Safety Profile and Bleeding Complications of Fondaparinux Versus Enoxaparin in Non-ST Elevation Acute Coronary Syndrome.

However, when all time points were pooled, the cumulative incidence of bleeding was substantially higher in the enoxaparin group (23.3%) compared to the fondaparinux group (6.9%), and this difference was highly significant (χ2=8.02, p=0.002).

also in 132,142 other papers

25.56%, p=0.050, borderline significant), statistical significance was not reached.

also in 11,409 other papers

71.3%), this did not reach statistical significance (χ2=3.03, p=0.055).

also in 111,027 other papers

During hospitalization, recurrent ischemia was observed in 17.8% of enoxaparin patients compared to 9.2% in the fondaparinux group, though this difference narrowly missed statistical significance (χ2=2.10, p=0.095).

also in 227 other papers

While total mortality differences showed a trend favoring fondaparinux, they did not reach statistical significance.

also in 53,322 other papers